股票代码：300016 股票简称：北陆药业 公告编号：2025-039 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 2024年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 1、北京北陆药业股份有限公司（以下简称"公司"）2024年度利润分配 预案已获2025年5月8日召开的2024年度股东大会审议通过，公司2024年度权益 分派方案为：以截至2024年12月31日总股本491,946,696股为基数，向全体股东 每10股派发现金股利0.5元人民币（含税），合计向全体股东派发现金红利 24,597,334.80元，不送红股、不进行资本公积金转增股本，剩余未分配利润结 转下一年度。若在分配方案实施前，公司总股本由于可转债转股、股份回购等 原因而发生变化的，公司将按照分配比例不变的原则对分配总额进行调整。 2、由于公司发行的可转换公司债券（债券简称"北陆转债"，债券代码 "123082"）处于转股期内，自2024年12月31日至本次权益分派实施申请日 （2025年5月9日）期间共计 ...

Group 1: Financial Performance - The company's revenue for 2024 reached 98,355.45 million, a year-on-year increase of 10.42% [2] - Net profit attributable to shareholders was 1,365.17 million, up 119.02% year-on-year, with the parent company's net profit at 5,635.84 million, increasing by 838.39% [2] - In Q1 2025, revenue was 28,268.07 million, showing a growth of 36.23% year-on-year, while net profit rose to 1,453.85 million, up 26.13% [2] Group 2: Profitability and Margins - The gross margin for 2024 was 47.67%, an increase of 0.66 percentage points compared to 2023 [3] - The company plans to enhance gross margins through continuous improvement in production processes and cost reduction [3] Group 3: Product Performance - Sales revenue from contrast agents reached 58,804.95 million in 2024, a growth of 9.87% year-on-year [3] - Sales of antidiabetic products grew by 33.24% year-on-year, attributed to successful bidding and subsequent contracts [4] Group 4: Research and Development - R&D expenses for 2024 were 6,923.81 million, a decrease of 43.40% compared to the previous year, due to a more stable phase in R&D and improved efficiency [5] - The company has 12 projects under review and 23 new R&D projects initiated [5] Group 5: Subsidiary Developments - The acquisition of Tianyuan Pharmaceutical increased the number of traditional Chinese medicine products to 59, with a focus on promoting unique products [8] - The construction of the production base for Luzhibao Pharmaceutical is ongoing, with trial production expected to start within the year [7] Group 6: Investor Relations and Governance - The total number of shareholders decreased by 7.37% by the end of Q1 2025, indicating a shift towards attracting more quality investors [10] - The company emphasizes a stable and scientific dividend policy to ensure sustainable returns to shareholders [10] Group 7: Debt Management - The company has sufficient funds to repay the principal and interest of convertible bonds due next year, ensuring no repayment risk [11]

北京北陆药业股份有限公司 债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2025-038 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开的日期和时间： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 （1）现场会议召开时间为：2025年5月8日（星期四）下午14：00 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具 体时间为2025年5月8日9：15—9：25、9：30—11：30、13：00—15：00；通 过深圳证券交易所互联网投票系统投票的时间为2025年5月8日上午9：15至下 午15：00期间的任意时间。 2、召开地点：北京市海淀区西直门北大街 32 号枫蓝国际写字楼 A 座 7 层 A1 会议室 3、会议召集人：公司董事会 2024年度股东大会决议公告 1、本次股东大会无增加、变更、否决提案的情况； 特别提示： 6、会议召开的合法、合规性：公司第八届董事会第二十五次会议审议通 过了《关于召开 2024 年度股东大会的议案》，本次股东大会 ...

法律意见书 北京市中伦律师事务所 关于北京北陆药业股份有限公司 2024 年年度股东大会的 法律意见书 致：北京北陆药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为北京北陆药业股份有限公 司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2024 年年度股东大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）《上市公司股东会规则》等相关法律、法规、规范性文件及 《北京北陆药业股份有限公司章程》（以下简称"《公司章程》"）的规定，对 本次股东大会进行见证并出具法律意见。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》 等法律、法规、规范性文件及《公司章程》的规定发表意见，不对会议审议的议 案内容以及该等议案所表述的事实或数据的真实性及准确性发表意见。本所经办 律师无法对网络投票股东资格进行核查，在参与网络投票的股东资格均符合《公 司法》等相关法律、行政法规、规范性文件及《公司章程》规定的前提下 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-037 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于2025年4月18日在巨 潮资讯网发布了《关于召开2024年度股东大会的通知》，为进一步保护投资者 的合法权益，方便公司股东行使股东大会表决权，现将股东大会的有关事项提 示如下： 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会 深圳证券交易所互联网投票系统投票的时间为2025年5月8日上午9：15至下午 15：00期间的任意时间。 5、召开方式：本次会议采取现场投票和网络投票相结合的方式 （1）现场投票：包括本人出席及通过填写授权委托书授权他人出席。 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （wltp.cninfo.com.cn）向全体股东提供网络形式的投票平台，股东可以在网络 投票时间内通过上述系统行使表决权。公司股东应选择现场投票、网络投票中 ...

Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0296 | 0.0235 | 25.96 | 0.0256 | | 每股净资产（元） | 0 | 3.15 | -100 | 3.37 | | 每股公积金(元) | 0.28 | 0.27 | 3.7 | 0.27 | | 每股未分配利润(元) | 1.60 | 1.58 | 1.27 | 1.80 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.83 | 2.08 | 36.06 | 1.88 | | 净利润(亿元) | 0.15 | 0.12 | 25 | 0.13 | | 净资产收益率(%) | 0.87 | 0.70 | 24.29 | 0.71 | 前十大流通股东累计持有： 16945.73万股，累计占流通股比： 34.5%，较上期变化： 354.36万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | ...

Financial Performance - The company's revenue for Q1 2025 reached ¥282,680,687.56, representing a year-on-year increase of 36.23% compared to ¥207,506,078.84 in the same period last year[4] - Net profit attributable to shareholders was ¥14,538,525.05, up 26.13% from ¥11,526,165.00 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥13,087,958.97, reflecting a 14.34% increase from ¥11,446,351.32 year-on-year[4] - Total operating revenue for the current period reached ¥282,680,687.56, a 36.2% increase from ¥207,506,078.84 in the previous period[26] - Net profit for the current period was ¥13,302,320.12, representing a 14.5% increase compared to ¥11,621,240.12 in the previous period[27] - The company reported a total comprehensive income of ¥13,302,320.12 for the current period, compared to ¥11,621,240.12 in the previous period, reflecting a growth of 14.5%[27] - Earnings per share (basic) rose to ¥0.0296, compared to ¥0.0235 in the previous period, reflecting a 26.0% increase[27] Cash Flow and Liquidity - The company's cash flow from operating activities was ¥44,381,775.02, an increase of 25.57% compared to ¥35,344,060.75 in the same period last year[4] - The net cash flow from operating activities was ¥44,381,775.02, an increase of 25.8% from ¥35,344,060.75 in the prior period[29] - Cash inflows from operating activities totaled ¥322,551,204.15, compared to ¥252,187,578.57 in the previous period, marking a 27.8% increase[29] - The increase in cash and cash equivalents at the end of the period was 111.57%, reaching ¥54,471.82 million[11] - The company's cash and cash equivalents increased to ¥544,718,169.73 from ¥257,459,047.29, representing a growth of approximately 111%[21] - The ending balance of cash and cash equivalents stood at $500.03 million, slightly down from $515.20 million in the prior period[30] - The net increase in cash and cash equivalents was $282.96 million, contrasting with a decrease of $216.53 million in the previous period[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,206,878,734.58, a 7.70% increase from ¥2,977,531,229.66 at the end of the previous year[6] - Total current assets rose to ¥1,407,376,183.43 from ¥1,171,178,271.53, indicating an increase of about 20%[21] - The company's total assets reached ¥3,206,878,734.58, up from ¥2,977,531,229.66, reflecting a growth of approximately 8%[22] - Total liabilities reached ¥1,362,576,283.36, an increase of 18.7% from ¥1,148,042,995.20[24] - Short-term borrowings increased to ¥215,119,142.22 from ¥140,019,395.38, marking a rise of about 54%[22] - The company's long-term equity investments slightly decreased to ¥195,996,208.94 from ¥196,640,803.29, showing a marginal decline[22] Research and Development - The company's R&D expenses for the period amounted to ¥2,140.04 million, a 54.07% increase year-on-year, driven by phase-specific investments in research[11] - Research and development expenses increased to ¥21,400,376.20, up 54.1% from ¥13,889,933.57 year-over-year[26] Market Strategy and Development - The company achieved growth through three core drivers: expanding market share in chemical generic drugs, rapid integration and expansion in traditional Chinese medicine through acquisitions, and successful international market development[11] - The company continues to implement a dual-driven strategy of chemical and traditional Chinese medicine, focusing on both domestic and international markets for sustainable growth[11] - The company plans to participate in centralized procurement in 16 provinces, which is expected to enhance market penetration[17] - The company received drug registration certificates for new products, including iodine-based injections, indicating ongoing product development[17][18] Inventory and Receivables - Inventory levels decreased to ¥354,585,925.90 from ¥362,094,049.65, a reduction of approximately 2%[21] - The company reported a decrease in accounts receivable from ¥170,277,582.02 to ¥160,640,425.63, a decline of about 6.5%[21] Other Information - The company has not reported any changes in the number of preferred shareholders or restricted shares during the period[15][16] - The company did not undergo an audit for the first quarter report[32] - The new accounting standards will be implemented starting from 2025[31] - The company's cash outflow related to investment activities included $227 million for other investment-related cash payments[30]

股票代码：300016 股票简称：北陆药业 公告编号：2025-035 债券代码：123082 债券简称：北陆转债 特此公告。 北京北陆药业股份有限公司 董事会 二○二五年四月二十五日 1 北京北陆药业股份有限公司 2025年第一季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司《2025 年第一季度报告》已于 2025 年 4 月 25 日在中国证监会指定的创业板信息披露网站上披露，请投资者注意查阅。 ...

北陆药业（300016）公告，2025年第一季度营业收入2.83亿元，同比增长36.23%。净利润1453.85万 元，同比增长26.13%。 ...